BPMC Blueprint Medicines
- 93.000
- +2.270+2.50%
- 94.990
- +1.990+2.14%
Blueprint Medicines News
Blueprint Medicines Is Maintained at Buy by Stifel
Blueprint Medicines Is Maintained at Buy by Stifel
Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments, the
Express News | Blueprint Medicines Corp : Stifel Raises Target Price to $130 From $120
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham
Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
Blueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease Treatments
Blueprint Medicines: Buy Rating Affirmed on BLU-808 Prospects and Strong Ayvakit Sales Forecast
Blueprint Prep Unveils the First AI Tutor Chatbot for NP Board Prep
The AI-powered chatbot, Blue, will expand to Blueprint's Sarah Michelle NP Reviews brand to help future nurse practitioners pass their exams. LOS ANGELES, April 23, 2024 /PRNewswire/ -- Blueprint Pre
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
-- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast
S&P 500 Futures Fall In Premarket Trading; CarMax, Fastenal Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Blueprint Medicines Corp. (BPMC) was up 5.9% in pre
Decoding 6 Analyst Evaluations For Blueprint Medicines
During the last three months, 6 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent
Express News | JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Blueprint Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 28.1% JMP Securities → $114 Reiterates Market Outperform → Market Outperform 02/26/2024 8.99% N
Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook
Blueprint Medicines Corporation (NASDAQ:BPMC): Is Breakeven Near?
We feel now is a pretty good time to analyse Blueprint Medicines Corporation's (NASDAQ:BPMC) business as it appears the company may be on the cusp of a considerable accomplishment. Blueprint Medicin
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH)
Analysis
Price Target
No Data
